Results 231 to 240 of about 27,891 (313)

Effects of Glucagon‐Like Peptide‐1 Receptor Agonists (Mono and Combination Therapy) on Energy Expenditure: A Scoping Review

Obesity Reviews, EarlyView.
ABSTRACT Introduction Weight loss results in reduced energy expenditure (EE) due to body composition alterations (e.g., fat‐free mass and fat mass losses) and mass‐independent adaptations in EE (e.g., hormones). Glucagon‐like peptide‐1 receptor agonists (GLP‐1RA) are indicated for obesity management; however, their effects on EE remain unclear ...
Flavio T. Vieira, ZhiDi Deng, Manfred J. Muller, Giovanna G. L. Bergamasco, Sarah Cawsey, Melania Manco, Steven B. Heymsfield, Carla M. Prado, Andrea M. Haqq   +8 more
wiley   +1 more source

Impact of Fibrotic Metabolic Dysfunction-Associated Steatohepatitis as a New Indication on Semaglutide Eligibility in the US Adult Population. [PDF]

Gastro Hep Adv
van Kleef LA, Michel M, Savas M, Pustjens J, Theel W, van Rossum EFC, Paik JM, Younossi ZM, Janssen HLA, Labenz C, Schattenberg JM, Brouwer WP.   +11 more
europepmc   +1 more source

A Systematic Review and Meta‐Analysis of Randomized Controlled Trials of Behavioral Interventions for the Management of Overweight and Obesity in Children That Are Delivered or Referred to by Health Providers in Primary Care

Obesity Reviews, EarlyView.
ABSTRACT Introduction Reducing childhood overweight and obesity prevalence is a global public health priority. This systematic review and meta‐analysis evaluated the effectiveness of behavioral weight management interventions delivered or referred to by health care providers in primary care settings.
Henrietta E. Graham, Claire D. Madigan, Kajal Gokal, Jessica F. Large, James Sanders, Chris J. McLeod, Natalie Pearson, Amanda J. Daley   +7 more
wiley   +1 more source

The GLP‐1 Receptor Agonist Paradox in Dermatology: Why We Cannot Afford the Knowledge Gap

International Journal of Dermatology, EarlyView.
Ramy Awadalla, Derek Davies
wiley   +1 more source

Association of Glucagon‐Like Peptide‐1 Receptor Agonists and Suicidality: A Systematic Review

Obesity Reviews, EarlyView.
ABSTRACT Introduction Increased risk of suicidality has been reported in association with glucagon‐like peptide receptor agonist (GLP‐1 RA) prescription. Herein, we conducted a comprehensive review evaluating reports of GLP‐1 RA prescription and suicidality.
Hezekiah C. T. Au, Yang Jing Zheng, Gia Han Le, Sabrina Wong, Kayla M. Teopiz, Angela T. H. Kwan, Joshua D. Rosenblat, Rodrigo B. Mansur, Hayun Choi, Roger S. McIntyre   +9 more
wiley   +1 more source

Community Pharmacists' Knowledge and Counseling Competence on GLP-1 Receptor Agonists in Obesity and Type 2 Diabetes Care in Türkiye: A Cross-Sectional Study. [PDF]

Diabetes Metab Syndr Obes
Bayram-Ozgur D, Demirtürk E, Sar Y.
europepmc   +1 more source

Low Weight Loss Response to Incretin Analogs: A Systematic Review

Obesity Reviews, EarlyView.
ABSTRACT The development of GLP‐1 and GIP analogs has been a significant breakthrough in type 2 diabetes and obesity pharmacotherapy. However, individual responses to these medications can vary widely. This systematic review examines factors associated with low or no weight loss response to GLP‐1 and GIP analogs. Key predictors of poor response include
Pamela S. Gaskin, Peter S. Chami
wiley   +1 more source

Comparative Efficacy and Safety of Once-Weekly Semaglutide Formulations in Indian Adults With Obesity: A Phase III, Randomized Non-inferiority Active-Controlled Study (Size Plus Study). [PDF]

Cureus
Kapoor N, Kalra S, Naskar A, Shaikh S, Das S, Kota S, Bhattacharya S, Bhattacharya R, Giri R, Karnik N, Parise G, Mangipudi A, Ghosh A, Dange A, Khandelwal D, Chaudhari M, Deogaonkar N, Shamanna P, Sorate S, Saklecha S, Samadhan S, Varade D, Shembalkar J, Bangar K, Lomte N, Mayabhate M, Kapure N, Sharma A, Vaddem R, Jaiswal M.   +29 more
europepmc   +1 more source

GLP‐1 Receptor Agonists and Weight Loss: A Critical Review of Mechanisms

Obesity Reviews, EarlyView.
ABSTRACT GLP‐1 receptor agonist medications have the potential to promote marked weight loss, but maximal and sustained benefit may be compromised by poor compliance and cessation of use. Development of next‐generation medications that address current obstacles to effective use and development of effective adjunct treatments will benefit from better ...
Giorgia Rutigliani, Tzu‐Wen L. Cross, Erica de Jong, Emily S. Glover, Ivan D. Mendoza, Mojisola Adisa, Keigo Tomoo, Xinyi Zhou, Richard D. Mattes   +8 more
wiley   +1 more source

Current Insights and Future Directions on the Role of GLP-1 Receptor Agonists in Chronic Kidney Disease. [PDF]

Int J Nephrol Renovasc Dis
Rajan K, Jutley AK, Holliday MW, Navaneethan SD.   +3 more
europepmc   +1 more source